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ABSTRACT 
The progress of five pharmaceutical compounds (bezafibrate, carbamazepine, diclofenac, 
ibuprofen and sulfasalazine) and one antibacterial agent (triclosan) were monitored through 
the treatment stages of a large sewage treatment works (STW) using activated sludge as well 
as in the receiving water both upstream and downstream of the effluent discharge. All except 
sulfasalazine were detected in the influent at concentrations ranging from 1.44-3.75 µg/L. 
The analysis of prescription data has been used as a tool to predict the amount of 
pharmaceuticals potentially released into the catchment of the investigated sewage treatment 
works and the results compared with the measured influent concentrations. A reduction in 
concentration between influent and final effluent samples (51-97%) indicates the variable 
removal of these compounds and therefore their potential to be discharged into receiving 
surface waters. The analysis of primary and final effluents highlight the important processes 
involved in the removal of pharmaceuticals and indicate that sorption processes are important 
for bezafibrate, carbamazepine and diclofenac. These three PPCPs were observed at higher 
concentrations (0.07-0.35 µg/L) downstream of the discharged effluent compared to upstream 
(0.02-0.04 µg/L) although the risks that these compounds pose in the environment are not yet 
fully understood. 
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INTRODUCTION 
The quality of natural waters is under threat from the chemical substances discharged in 
industrial and domestic wastes. As a consequence threshold water quality standards are 
enforced under legislation (e.g. The Water Framework Directive (2000/60/EC) (Defra, 2009) 
and Clean Water Act Section 402 (US Environmental Protection Agency, 2009)). Currently 
legislation is focused on reducing ‘priority pollutants’ which include a wide range of 
persistent organic compounds and heavy metals. However, new emerging pollutants which 
are gaining increasing attention include pharmaceutical compounds and the active ingredients 
used in personal care products (collectively termed PPCPs) (Ternes, 1998). Through 
processes such as excretion or disposal of unused or expired drugs, many pharmaceuticals 
and their metabolites find their way to sewage treatment plants where they are rarely 
completely eliminated. This results in their continuous release into the aquatic environment 
through the discharge of final treated effluents. PPCPs also accumulate in sewage sludges and 
ultimately can be released into the environment through the application of the sludge as an 
agricultural fertilizer.  
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There are increasing numbers of publications reporting the detection of trace levels of PPCPs 
in the influents to sewage treatment works (STW) (Karthikeyan and Meyer, 2006; Zorita et. 
al., 2009), the effluents from STWs (Clara et. al., 2005) and in river waters (Gros et. al., 2006 
and 2007) at typical concentrations of nanogram per litre to low microgram per litre. 
Although these low concentrations may not have a therapeutic effect on humans, the potential 
affect on aquatic ecosystems is still relatively unclear. Despite the lack of full impact related 
data, the use of these compounds will continue to increase with increasing population size 
and demand and they will ultimately end up in natural waters. Prescribed pharmaceuticals in 
human medicine alone have risen in cost in the USA from $433 billion in 2002 to $808 
billion in 2009 (IMS Health Market Prognosis, 2009) and new pharmaceutically active 
substances are continually being developed and introduced into the market place.  This paper 
examines the passage of 6 PPCPs (carbamazepine, sulfasalazine, bezafibrate, diclofenac, 
triclosan and ibuprofen) through a large sewage treatment plant and assesses the impact of the 
treated effluent on the receiving water by comparing the pollutant concentrations both 
upstream and downstream of the discharged effluent.  
 
 
METHODOLOGY 
 
Sample location and collection 
Wastewater samples were collected from a large sewage treatment works (STW) in London 
at four points through the treatment process (influent, primary effluent, secondary effluent 
and final effluent). Surface water samples were collected both upstream and downstream of 
the effluent discharge. The STW receives approximately 244,000 m3 per day from a 399 km2 
catchment serving a total population of 870,000.  The works applies primary sedimentation, 
followed by secondary activated sludge (13 h) before discharge. All samples were collected 
in clean amber 2.5 L bottles, filtered on the day of collection and stored at 4°C until 
extraction (within 4 days). 
 
Chemicals and reagents 
Methanol, acetonitrile, formic acid and ammonium acetate were purchased from Fisher 
Scientific UK Ltd (Leicestershire, UK) and were either HPLC or LCMS grade. 
Pharmaceutical standards (purity ≥ 95% HPLC) of bezafibrate, carbamazepine, diclofenac, 
ibuprofen, sulfasalazine and triclosan were purchased from Sigma-Aldrich (Dorset, UK). 
Stock solutions (200 µg/mL) of all the analytes were prepared in LCMS grade methanol and 
stored at -80°C. Spiking solutions and external standards were prepared from the stock 
solution and diluted with 5% (v/v) methanol in LCMS grade water on the day of extraction 
and stored at 4°C. Samples were filtered with glass microfiber filters (1.2 µm) from Whatman 
Ltd, UK and extracted with 500mg/6 mL Strata-X cartridges purchased from Phenomenex, 
UK. 
 
Sample extraction 
Samples were divided into 6 equal aliquots (100 mL for the influent, 200 mL for the effluent 
and 1000 mL for the surface water) and spiked at varying concentrations with the spiking 
solution before extraction. Strata-X cartridges were first conditioned with 6 mL methanol and 
equilibrated with 6 mL LCMS grade water before samples were percolated through at an 
approximate flow rate of 1-2 mL minute using a vacuum extraction manifold (Phenomenex, 
UK). The sorbent was washed with 6 mL water and dried under vacuum for at least 30 
minutes prior to extraction with methanol (10 mL). The resulting extract was evaporated 
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under a gentle nitrogen stream using a TurboVap (Biotage, Sweden) at 35°C and 
reconstituted with 0.2 mL 5% (v/v) methanol in LCMS grade water, before transferring to 0.2 
µm nylon Mini-UniPrep filter vials (Whatman Ltd) for analysis. 
 
Analysis 
Analysis of the extracts was performed with reverse phase high performance liquid 
chromatography mass spectrometry LC-MSn with electrospray ionization in positive (+ve) 
and negative (-ve) ionization modes (LC2010, Shimadzu).  
 
The PPCPs were separated with a Kinetex 2.1 mm x 50 mm C18 column (Phenomenex, UK). 
For those compounds (bezafibrate, carbamazepine, diclofenac and sulfasalazine) analysed 
with positive (+ve) ionization, a mobile phase of water (A) and acetonitrile (B) with 0.1% 
formic acid was used. The solvent gradient started at 5% B and reached 67% B in 20 mins 
before increasing to 95% B for 5 mins and then returning to 5% B for 10 mins. For ibuprofen 
and triclosan which were analysed using negative (-ve) ionisation, a mobile phase of water (A) 
and acetonitrile (B) with 10 mM ammonium acetate was used. A solvent gradient increasing 
from 5 to 50% B was applied during 15 mins followed by 100% B for 5 mins and then 
column re-equilibration at 5% B for 10 mins. The column was maintained at 30°C with a 
flow rate of 0.2 mL/min and an injection volume of 10 µL.  
 
Method validation  
The target compounds were monitored using their parent ion in selective ion monitoring 
(SIM) mode. In positive mode, the following single parent ions [M+H]+ were monitored: 
bezafibrate: 362, carbamazepine: 237, diclofenac: 296 and sulfasalazine: 399. In negative 
mode, ibuprofen and triclosan were monitored with parent ions [M+H]- at 205 and 287, 
respectively. Quantification of the compounds of interest was performed using the standard 
addition method. Different concentrations were spiked into separate aliquots of each sample. 
The real analyte concentration was then determined by linear regression. At least five 
concentration points were used to check the linear range of the method and r2 values higher 
than 0.95 were obtained. To evaluate the method reproducibility (precision) for the individual 
compounds, surface water samples and effluents were spiked at 100 and 600 ng/L, 
respectively and divided into aliquots for separate extraction and analysis. It was difficult to 
determine the LOQ for effluent and surface waters, as the samples already contained the 
compounds of interest. Therefore, LOQs were estimated from different samples using signal-
to-noise ratios of 10. The method validation data is presented in Table 1. 
 
Table 1. The linear range, method precision (%RSD) and limit of quantification (LOQ) 
determined for the selected PPCPs in sewage effluent and river water.  
Drug r2 for linear range 
 (5 point calibration) 
Precision (RSD %) 
 (n=3) 
LOQ 
(ng/L) 
 Effluent River 
water 
Effluent River 
water 
Effluent River 
water 
Bezafibrate 0.9547 0.9983 3.4 2.7 100 5 
Carbamazepine 0.9838 0.9787 6.0 2.5 100 5 
Diclofenac 0.9813 0.9975 13.0 1.9 150 19 
Ibuprofen 0.9885 0.9968 21.0 9.0 242 68 
Sulfasalazine 0.9670 0.9634 54.2 40.9 150 65 
Triclosan 0.9949 0.9752 17.4 11.0 250 80 
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n= number of samples. LOQ was estimated for each sample matrix (effluent or river water) at a signal to noise 
ratio 10. 
 
 
RESULTS AND DISCUSSION 
The concentrations of the six selected PPCPs detected in the influent, effluents and surface 
water samples are presented in Figure 1. Complete data sets have been obtained for 
carbamazepine, bezafibrate and diclofenac. The influent concentrations for sulfasalazine 
could not be reliably determined due to the poor extraction efficiency from raw sewage. For 
triclosan and ibuprofen, only the raw and settled sewage samples demonstrated 
concentrations which were clearly above the levels of quantification. The upstream 
concentrations plotted in Figure 1 have been increased by a factor of 10 for clarity. 
 
 
Figure 1. Concentrations of selected PPCPs in the influent and effluents of a sewage 
treatment plant and in the receiving water upstream and downstream of the final effluent 
release point.  
Comparison of predicted concentrations and measured concentrations 
The range of monitored sewage treatment influent concentrations (1.44 µg/L for 
carbamazepine to 3.75 µg/L for bezafibrate) is consistent with previously reported values 
(Clara et. al., 2005). Several factors can influence these concentrations including 
consumption levels, population characteristics and the age and design of the sewer system. 
Consumption data are considered to be a critical influencing parameter but this information 
can be difficult to locate. For example, in England it is difficult to obtain a reliable estimate 
of the tonnes of pharmaceuticals used per year and currently a central or regional record of 
pharmaceutical use by hospitals or over-the-counter medicines is not readily accessible 
making it difficult to quantify the amount of pharmaceuticals entering the environment. 
However, prescription analysis and cost (PACT) data is collated from all the prescriptions 
dispensed in the community (community pharmacists and dispensing doctors) in England 
(NHS Information Centre, 2009) and is readily available. Using PACT data, the quantities of  
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Table 2. Prescription data for selected PPCPs in England for 2007 and estimated influent 
concentrations to a sewage treatment works. 
 
 
 
PPCP 
 
 
 
Class 
 
 
Tonnes/year 
(2007) 
 
 
% excreted 
unchanged 
Predicted 
maximum 
concentration 
(µg/L) 
Bezafibrate Lipid regulating drug 10 50 ~2.0 
Carbamazepine Anticonvulsant 55 <10 ~10.0 
Diclofenac Non-steroidal anti-inflammatory 30 + 15 ~6.0 
Ibuprofen Non-steroidal anti-inflammatory 108 + <10 ~20.0 
Sulfasalazine Sulfanilamide 49 15 ~9.20 
Triclosan Antibacterial agent ++ n/a n/a 
+ Available without prescription, ++ active present in numerous cosmetic products, n/a not available. 
 
bezafibrate, carbamazepine, diclofenac, ibuprofen and sulfasalazine used per annum have 
been estimated (Table 2) and shown to vary between 10 and 108 tonnes/year in 2007, 
indicating that there are significant differences in the types and amounts of pharmaceuticals 
consumed. By scaling down these estimates to the sewage treatment works catchment 
containing 870,000 population equivalent and taking into account the typical dry weather 
flow of 244,000 m3/day, a predicted maximum concentration entering the STW has been 
estimated (Table 2). The observed influent concentrations for carbamazepine and ibuprofen 
(1.44 µg/L and 1.85 µg/L ) are consistent with the predicted maximum concentration for the 
catchment area (~10 and 20 µg/L) when the fact that <10 % of these compounds are excreted 
unchanged is taken into account. However, ibuprofen is also available without prescription 
and therefore higher influent concentrations could be expected. 
 
The predicted maximum concentration for diclofenac (~6.0 µg/L) was higher than measured 
in the influent concentration (1.54 µg/L) but this would reduce to less than 1 µg/L when the 
percentage excreted is taken into account, The reverse is observed for bezafibrate where the 
predicted concentration (~2.0 µg/L) is lower than measured in the influent (3.75 µg/L) and 
this difference would be magnified when the percentage of bezafibrate excreted unchanged 
(50%) is taken into account. A predicted maximum concentration for triclosan was not 
estimated as this compound is present as an active component in many cosmetic and cleaning 
products and is therefore accessible without prescription. It is also generally applied 
externally rather than being ingested. If over the counter drugs sales and regional and 
seasonal pharmaceutical usage data was available a more accurate prediction could be made. 
 
Reduction of PPCPs through STW processes 
Where the relevant monitoring date is available, the general trend observed is a decrease in 
PPCP concentrations through the sewage treatment process with overall reductions of 97%, 
84%, 69% and 51% for bezafibrate, ibuprofen, diclofenac and carbamazepine, respectively 
between raw sewage and the final treated effluent (secondary effluent for ibuprofen) (Figure 
1). The removal of PPCPs from wastewaters is a complex process but two particularly 
important mechanisms are sorption and biodegradation at the primary and secondary 
treatment stages, respectively. Carbamazepine was only reduced by 11% during activated 
sludge treatment (Figure 1) indicating that it is not easily biodegraded under the applied 
conditions. In contrast, 40% of carbamazepine was removed by primary sedimentation 
suggesting that sorption is a more important removal mechanism. This is consistent with both 
the soil organic carbon-water partitioning coefficient (Koc) for carbamazepine (510) and the 
sludge-water adsorption coefficient (Kd) (25 mL/g) which are indicative of a moderate level 
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of adsorption to activated sludge. It has been reported that carbamazepine is not removed 
during the sewage treatment process (Radjenovic et. al., 2007) but this clearly varies between 
treatment plants due to influencing factors being operating conditions, age of sludge and 
treatment plant design.  
 
In the removal of bezafibrate both primary and secondary sewage treatment processes 
contributed to the high removal rate (97 %) and this is consistent with removal values 
reported elsewhere (Castiglioni et.al., 2004). Sedimentation reduced the bezafibrate 
concentration by 48% and a similar decrease was observed during activated sludge treatment. 
Primary sedimentation processes were also important in the removal of diclofenac (57%) 
which is consistent with the adsorption potential to suspended solids and sediment predicted 
by a Koc value of 830. The total removal percentage (69%) observed for diclofenac 
throughout the treatment process agrees with the results reported by Roberts and Thomas 
(2006) although the slight increase in diclofenac concentration between secondary and final 
effluent is unexpected and contrary to previous (Kasprzyk-Hordern et.al., 2009).  
 
The incomplete removal of PPCP compounds in the sewage treatment process will pose 
problems for the receiving waters as evidenced by the consistently increasing downstream 
levels. The limited removal of bezafibrate, carbamazepine and diclofenac resulted in 
downstream concentrations of 0.07, 0.28 and 0.35 µg/L respectively compared to 0.02, 0.04 
and 0.04 µg/L upstream.  
 
 
CONCLUSIONS 
The analysis of prescription data has indicated the high quantities of 6 PPCPs (bezafibrate, 
carbamazepine, diclofenac, ibuprofen, sulfasalazine and triclosan) prescribed per year that 
could ultimately arrive at sewage treatment plants following ingestion and excretion. The 
analysis of influents, effluents and samples collected both upstream and downstream of the 
effluent discharge from a large sewage plant show that these compounds are incompletely 
eliminated. Although the percentage removed during sewage treatment depends on a number 
of factors including the type of treatment and the population characteristics, sorption is shown 
to be an important removal process. A comparison of PPCP concentrations upstream and 
downstream of the effluent discharge suggests the potential for pharmaceuticals to 
accumulate in receiving waters. 
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